Connor Clark & Lunn Investment Management Ltd. Has $6.33 Million Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 16.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,434,625 shares of the company’s stock after purchasing an additional 205,789 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in GoodRx were worth $6,327,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in GoodRx by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 8,624,872 shares of the company’s stock worth $38,036,000 after purchasing an additional 251,833 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock valued at $9,264,000 after acquiring an additional 369,553 shares in the last quarter. Geode Capital Management LLC raised its holdings in GoodRx by 9.1% in the 4th quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company’s stock valued at $4,986,000 after acquiring an additional 89,032 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in GoodRx by 303.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company’s stock valued at $4,936,000 after acquiring an additional 798,261 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in GoodRx by 69.1% in the 4th quarter. Two Sigma Advisers LP now owns 754,000 shares of the company’s stock valued at $3,506,000 after acquiring an additional 308,000 shares in the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.

Insider Activity at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.17% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on GDRX. UBS Group dropped their price objective on GoodRx from $6.00 to $5.25 and set a “neutral” rating for the company in a report on Tuesday, May 13th. Wells Fargo & Company dropped their price objective on GoodRx from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. Raymond James Financial cut GoodRx from a “strong-buy” rating to an “outperform” rating in a report on Friday. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $6.00 price target on shares of GoodRx in a report on Monday. Finally, The Goldman Sachs Group lowered their price target on GoodRx from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, May 9th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.18.

GoodRx Trading Up 0.6%

Shares of GDRX stock opened at $3.50 on Wednesday. The firm has a market capitalization of $1.25 billion, a P/E ratio of 35.00, a P/E/G ratio of 1.43 and a beta of 1.24. GoodRx Holdings, Inc. has a twelve month low of $3.31 and a twelve month high of $8.80. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75. The stock’s fifty day simple moving average is $4.59 and its 200 day simple moving average is $4.53.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same quarter last year, the firm posted $0.08 EPS. The company’s quarterly revenue was up 1.2% on a year-over-year basis. As a group, sell-side analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.